Reparative resynchronization in ischemic heart failure: An emerging strategy

Research output: Contribution to journalArticle

Abstract

Cardiac dyssynchrony refers to disparity in cardiac wall motion, a serious consequence of myocardial infarction associated with poor outcome. Infarct-induced scar is refractory to device-based cardiac resynchronization therapy, which relies on viable tissue. Leveraging the prospect of structural and functional regeneration, reparative resynchronization has emerged as a potentially achievable strategy. In proof-of-concept studies, stem-cell therapy eliminates contractile deficit originating from infarcted regions and secures long-term synchronization with tissue repair. Limited clinical experience suggests benefit of cell interventions in acute and chronic ischemic heart disease as adjuvant to standard of care. A regenerative resynchronization option for dyssynchronous heart failure thus merits validation.

Original languageEnglish (US)
Pages (from-to)1055-1060
Number of pages6
JournalExpert Opinion on Biological Therapy
Volume14
Issue number8
DOIs
StatePublished - 2014

Fingerprint

Cardiac resynchronization therapy
Cardiac Resynchronization Therapy Devices
Heart Failure
Tissue
Standard of Care
Cell- and Tissue-Based Therapy
Stem cells
Refractory materials
Cicatrix
Myocardial Ischemia
Regeneration
Synchronization
Repair
Stem Cells
Myocardial Infarction

Keywords

  • Biologics
  • Cardiac resynchronization therapy
  • Clinical trial
  • Dyssynchrony
  • Heart failure
  • Myocardial infarction
  • Regenerative medicine
  • Stem cells

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Reparative resynchronization in ischemic heart failure : An emerging strategy. / Yamada, Satsuki; Terzic, Andre.

In: Expert Opinion on Biological Therapy, Vol. 14, No. 8, 2014, p. 1055-1060.

Research output: Contribution to journalArticle

@article{3429d20a1b184646b87bc22ec1c7ad52,
title = "Reparative resynchronization in ischemic heart failure: An emerging strategy",
abstract = "Cardiac dyssynchrony refers to disparity in cardiac wall motion, a serious consequence of myocardial infarction associated with poor outcome. Infarct-induced scar is refractory to device-based cardiac resynchronization therapy, which relies on viable tissue. Leveraging the prospect of structural and functional regeneration, reparative resynchronization has emerged as a potentially achievable strategy. In proof-of-concept studies, stem-cell therapy eliminates contractile deficit originating from infarcted regions and secures long-term synchronization with tissue repair. Limited clinical experience suggests benefit of cell interventions in acute and chronic ischemic heart disease as adjuvant to standard of care. A regenerative resynchronization option for dyssynchronous heart failure thus merits validation.",
keywords = "Biologics, Cardiac resynchronization therapy, Clinical trial, Dyssynchrony, Heart failure, Myocardial infarction, Regenerative medicine, Stem cells",
author = "Satsuki Yamada and Andre Terzic",
year = "2014",
doi = "10.1517/14712598.2014.922536",
language = "English (US)",
volume = "14",
pages = "1055--1060",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Reparative resynchronization in ischemic heart failure

T2 - An emerging strategy

AU - Yamada, Satsuki

AU - Terzic, Andre

PY - 2014

Y1 - 2014

N2 - Cardiac dyssynchrony refers to disparity in cardiac wall motion, a serious consequence of myocardial infarction associated with poor outcome. Infarct-induced scar is refractory to device-based cardiac resynchronization therapy, which relies on viable tissue. Leveraging the prospect of structural and functional regeneration, reparative resynchronization has emerged as a potentially achievable strategy. In proof-of-concept studies, stem-cell therapy eliminates contractile deficit originating from infarcted regions and secures long-term synchronization with tissue repair. Limited clinical experience suggests benefit of cell interventions in acute and chronic ischemic heart disease as adjuvant to standard of care. A regenerative resynchronization option for dyssynchronous heart failure thus merits validation.

AB - Cardiac dyssynchrony refers to disparity in cardiac wall motion, a serious consequence of myocardial infarction associated with poor outcome. Infarct-induced scar is refractory to device-based cardiac resynchronization therapy, which relies on viable tissue. Leveraging the prospect of structural and functional regeneration, reparative resynchronization has emerged as a potentially achievable strategy. In proof-of-concept studies, stem-cell therapy eliminates contractile deficit originating from infarcted regions and secures long-term synchronization with tissue repair. Limited clinical experience suggests benefit of cell interventions in acute and chronic ischemic heart disease as adjuvant to standard of care. A regenerative resynchronization option for dyssynchronous heart failure thus merits validation.

KW - Biologics

KW - Cardiac resynchronization therapy

KW - Clinical trial

KW - Dyssynchrony

KW - Heart failure

KW - Myocardial infarction

KW - Regenerative medicine

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=84904023066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904023066&partnerID=8YFLogxK

U2 - 10.1517/14712598.2014.922536

DO - 10.1517/14712598.2014.922536

M3 - Article

C2 - 24840208

AN - SCOPUS:84904023066

VL - 14

SP - 1055

EP - 1060

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 8

ER -